Cybin announces up to usd$35 million at-the-market equity program

Toronto--(business wire)--cybin inc. (neo: cybn) (nyse american: cybn) (“cybin” or the “company”), a biopharmaceutical company focused on progressing “psychedelics to therapeuticstm”, announced today that it has established an at-the-market equity program (the “atm program”) that allows cybin to issue and sell up to usd$35,000,0000 of common shares (“shares”) in the capital of the company from treasury to the public, from time to time, through the agents (as defined below). all shares sold unde
CYBN Ratings Summary
CYBN Quant Ranking